In YAP/TAZ-dependent breast cancers, combinations of dasatinib, fluvastatin, and pazopanib compounds with each other or with other anti-cancer drugs efficiently reduced the YAP/TAZ-TEAD-dependent reporter activity [104]. Here, YAP1 is linked to cancer.